{"id":7456,"date":"2025-04-07T13:10:00","date_gmt":"2025-04-07T11:10:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/"},"modified":"2025-04-07T13:10:00","modified_gmt":"2025-04-07T11:10:00","slug":"fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/","title":{"rendered":"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien"},"content":{"rendered":"
\n

Nanexa AB meddelar att initiala observationer i fas I-studien visar att 30 mg dosen av NEX-22, en depotformulering av liraglutid, har tolererats v\u00e4l av patienter med typ 2-diabetes som inte tidigare f\u00e5tt GLP-1 behandling.<\/strong><\/p>\n<\/div>\n

\n

En nackdel med liraglutid givet som dagliga injektioner \u00e4r en h\u00f6g f\u00f6rekomst av tidiga gastrointestinala biverkningar med illam\u00e5ende och diarr\u00e9 och kr\u00e4ver en f\u00f6rsiktig dos\u00f6kning till den effektiva dagsdosen (1,2 mg). Efter en injektion av NEX-22 med 30 mg liraglutid frisatt \u00f6ver en m\u00e5nad, observerades inga fall av illam\u00e5ende, kr\u00e4kningar eller diarr\u00e9 hos de tre doserade patienterna.<\/p>\n

Tv\u00e5 patienter upplevde minskad aptit, en av dem i kombination med halsbr\u00e4nna. Samtliga observationer var milda och \u00f6verg\u00e5ende och \u00e4r \u00e4ven vanligen f\u00f6rekommande vid behandling med GLP-1 l\u00e4kemedel. Observationer av injektionsst\u00e4llet visar \u00e4ven att 30 mg dosen av NEX-22 tolererats v\u00e4l, med endast begr\u00e4nsade hudreaktioner av mindre och \u00f6verg\u00e5ende karakt\u00e4r.<\/p>\n

"Det h\u00e4r \u00e4r mycket positiva resultat!", s\u00e4ger David Westberg, vd p\u00e5 Nanexa. "Att NEX-22 kan administreras vid en dos p\u00e5 30 mg liraglutid utan att orsaka illam\u00e5ende, kr\u00e4kningar och diarr\u00e9, som alla \u00e4r vanliga gastrointestinala biverkningar med GLP-1, visar p\u00e5 stora potentiella f\u00f6rdelar. Vi ser fram emot att vidare presentera alla resultat fr\u00e5n studien."<\/p>\n

Uppf\u00f6ljningen av patienter forts\u00e4tter med att f\u00f6lja koncentrationen av liraglutid i blodet under drygt en m\u00e5nad, tillsammans med utv\u00e4rdering av s\u00e4kerhet och tolerabilitet.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar att initiala observationer i fas I-studien visar att 30 mg dosen av NEX-22, en depotformulering av liraglutid, har tolererats v\u00e4l av patienter med typ 2-diabetes som inte tidigare f\u00e5tt GLP-1 behandling.<\/p>\n","protected":false},"template":"","class_list":["post-7456","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nFortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar att initiala observationer i fas I-studien visar att 30 mg dosen av NEX-22, en depotformulering av liraglutid, har tolererats v\u00e4l av patienter med typ 2-diabetes som inte tidigare f\u00e5tt GLP-1 behandling.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\\\/\",\"name\":\"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-04-07T11:10:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/","og_locale":"sv_SE","og_type":"article","og_title":"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien - Nanexa AB","og_description":"Nanexa AB meddelar att initiala observationer i fas I-studien visar att 30 mg dosen av NEX-22, en depotformulering av liraglutid, har tolererats v\u00e4l av patienter med typ 2-diabetes som inte tidigare f\u00e5tt GLP-1 behandling.","og_url":"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/","url":"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/","name":"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-04-07T11:10:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/fortsatt-god-tolerabilitet-av-nex-22-vid-30-mg-dos-av-liraglutid-i-nex-22-studien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}